JP Patent

JP6197971B1 — Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤

Assigned to Ono Pharmaceutical Co Ltd · Expires 2017-09-20 · 9y expired

What this patent protects

【課題】ＫＣＮＱ２〜５チャネルに対し強い開口作用を有する化合物の提供。【解決手段】式（Ｉ）で表される化合物。（Ｘ1、Ｘ2はＮ等；Ｒ11はＮＨ2等；Ｒ2〜Ｒ5は各々独立にハロゲンで置換／非置換のＣ１〜４アルキル基等；Ｙは結合手等；Ｒ8はＨ等；Ｒ9はＣ１〜６アルキル基等）【選択図】なし

USPTO Abstract

【課題】ＫＣＮＱ２〜５チャネルに対し強い開口作用を有する化合物の提供。【解決手段】式（Ｉ）で表される化合物。（Ｘ1、Ｘ2はＮ等；Ｒ11はＮＨ2等；Ｒ2〜Ｒ5は各々独立にハロゲンで置換／非置換のＣ１〜４アルキル基等；Ｙは結合手等；Ｒ8はＨ等；Ｒ9はＣ１〜６アルキル基等）【選択図】なし

Drugs covered by this patent

vibegron (VIBEGRON)

Patent Metadata

Patent number: JP6197971B1
Jurisdiction: JP
Classification: —
Expires: 2017-09-20
Drug substance claim: No
Drug product claim: No
Assignee: Ono Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.